Business Description
Kuros Biosciences Ltd
ISIN : CH0325814116
Total Employee Number:
178Description
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.68 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.16 | |||||
Interest Coverage | 24.38 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 10.16 | |||||
Beneish M-Score | -1.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 88 | |||||
3-Year FCF Growth Rate | 32.6 | |||||
3-Year Book Growth Rate | 4.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 152.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 34.48 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.24 | |||||
9-Day RSI | 52.12 | |||||
14-Day RSI | 47.53 | |||||
3-1 Month Momentum % | -3.2 | |||||
6-1 Month Momentum % | -21.6 | |||||
12-1 Month Momentum % | -21.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.96 | |||||
Quick Ratio | 1.45 | |||||
Cash Ratio | 0.45 | |||||
Days Inventory | 311.6 | |||||
Days Sales Outstanding | 51.89 | |||||
Days Payable | 196.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -0.22 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.6 | |||||
Operating Margin % | 6.13 | |||||
Net Margin % | 1.75 | |||||
EBITDA Margin % | 5.99 | |||||
FCF Margin % | -1.98 | |||||
OCF Margin % | -0.31 | |||||
ROE % | 3.64 | |||||
ROA % | 2.43 | |||||
ROIC % | 5.62 | |||||
3-Year ROIIC % | 43.62 | |||||
ROC (Joel Greenblatt) % | 37.77 | |||||
ROCE % | 7.09 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 276.41 | |||||
Forward PE Ratio | 64.82 | |||||
PE Ratio without NRI | 322.5 | |||||
PS Ratio | 5.53 | |||||
PB Ratio | 8.97 | |||||
Price-to-Tangible-Book | 17.44 | |||||
EV-to-EBIT | 138.15 | |||||
EV-to-EBITDA | 84.93 | |||||
EV-to-Revenue | 5.09 | |||||
EV-to-FCF | -243.03 | |||||
Price-to-GF-Value | 0.5 | |||||
Price-to-Median-PS-Value | 0.42 | |||||
Price-to-Graham-Number | 15.74 | |||||
| Price-to-Net-Current-Asset-Value | 22.78 | |||||
Earnings Yield (Greenblatt) % | 0.73 | |||||
FCF Yield % | -0.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kuros Biosciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 146.058 | ||
| EPS (TTM) (CHF) | 0.07 | ||
| Beta | -0.1112 | ||
| 3-Year Sharpe Ratio | 1.49 | ||
| 3-Year Sortino Ratio | 4.59 | ||
| Volatility % | 41.12 | ||
| 14-Day RSI | 47.53 | ||
| 14-Day ATR (CHF) | 0.885036 | ||
| 20-Day SMA (CHF) | 19.45025 | ||
| 12-1 Month Momentum % | -21.2 | ||
| 52-Week Range (CHF) | 17.74 - 34.14 | ||
| Shares Outstanding (Mil) | 39.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kuros Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kuros Biosciences Ltd Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| 0.01:1 Stock Split | 2016-06-23 | 26.56 (+0.00%) |
Show
Entries
Kuros Biosciences Ltd Frequently Asked Questions
What is Kuros Biosciences Ltd(CHIX:KURNz)'s stock price today?
The current price of CHIX:KURNz is CHF19.36. The 52 week high of CHIX:KURNz is CHF34.14 and 52 week low is CHF17.74.
When is next earnings date of Kuros Biosciences Ltd(CHIX:KURNz)?
The next earnings date of Kuros Biosciences Ltd(CHIX:KURNz) is .
Does Kuros Biosciences Ltd(CHIX:KURNz) pay dividends? If so, how much?
Kuros Biosciences Ltd(CHIX:KURNz) does not pay dividend.
Press Release
Articles on Kuros Biosciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers